Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : T/FIF, a New Plateau -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (972)	2/20/2002 11:09:24 AM
From: scaram(o)uche	Respond to of 2243

9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 1,139,057(1) -------------------------------------------------------------------------------- 10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES* \|_\| -------------------------------------------------------------------------------- 11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 6.8% -------------------------------------------------------------------------------- 12 TYPE OF REPORTING PERSON* IN -------------------------------------------------------------------------------- *SEE INSTRUCTIONS BEFORE FILLING OUT (1) Lindsay A. Rosenwald, M.D., is the chairman, CEO and sole stockholder of Paramount CapitalAsset Management, Inc. ("PCAM"). PCAM is the General Partner to Aries Domestic Fund, a limited partnerships incorporated in Delaware and Investment Manager to the Aries Master Fund II, a Cayman Islands exempted company. Accordingly, Dr. Rosenwald's beneficial ownership consists of 171,666 shares of Common Stock and convertible securities to purchase 190,148 of Common Stock owned directly by the Aries Master Fund II; 10,774 shares of Common Stock and convertible securities to purchase 103,472 of Common Stock owned directly by the Aries Domestic Fund; 358,245 shares of Common Stock beneficially owned by RAQ, LLC, for which Dr. Rosenwald is the sole and managing member; and 238,118 shares of Common Stock and convertible securities to purchase 15, 804 shares of Common Stock owned directly by Dr. Rosenwald; 2 3 ITEM 1(a). NAME OF ISSUER: <PAGE> ITEM 1(a). NAME OF ISSUER: Palatin Technologies, Inc.